Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Rheumatoid arthritis

IL-6 inhibition in RA—déjà vu all over again?

Nature Reviews Rheumatology volume 11, pages 321–322 (2015)Cite this article

Subjects

In a phase II–III trial, a novel antibody targeting IL-6 receptor α (IL-6Rα), sarilumab, conferred clinical, functional and structural benefits in rheumatoid arthritis. These results, though, seem quite similar to those for tocilizumab, the existing anti-IL-6Rα antibody, as well as for other agents currently in development that target this same pathway.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Antibodies directed against IL-6 signalling.

References

  1. Genovese, M. C. et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. http://dx.doi.org/10.1002/art.39093.

  2. Huizinga, T. W. et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY part A trial. Ann. Rheum. Dis. 73, 1626–1634 (2014).

    Article  CAS  Google Scholar 

  3. Schoels, M. M. et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann. Rheum. Dis. 72, 583–589 (2013).

    Article  CAS  Google Scholar 

  4. Smolen, J. S. et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. 72, 482–492 (2013).

    Article  CAS  Google Scholar 

  5. Genovese, M. C. et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase IIb study. Ann. Rheum. Dis. 73, 1607–1615 (2014).

    Article  CAS  Google Scholar 

  6. Mease, P. et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann. Rheum. Dis. 71, 1183–1189 (2012).

    Article  CAS  Google Scholar 

  7. Smolen, J. S., Weinblatt, M. E., Sheng, S., Zhuang, Y. & Hsu, B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann. Rheum. Dis. 73, 1616–1625 (2014).

    Article  CAS  Google Scholar 

  8. Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375–83 (2011).

    Article  CAS  Google Scholar 

  9. Ruderman, E. M. Do we really need five TNF antagonists? Rheumatology (Oxford) 49, 1028–1029 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, 675 North St Clair, Suite 14-100, Chicago, 60611, IL, USA

    Eric M. Ruderman

Authors
  1. Eric M. Ruderman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eric M. Ruderman.

Ethics declarations

Competing interests

The author declares that he has acted as a consultant for AbbVie, Amgen, Celgene, Janssen, Lilly, Medac, Novartis, Pharmacyclics and Vertex, and has received grant or research support from AbGenomics, Amgen, Celgene and Pharmacyclics.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruderman, E. IL-6 inhibition in RA—déjà vu all over again?. Nat Rev Rheumatol 11, 321–322 (2015). https://doi.org/10.1038/nrrheum.2015.58

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2015.58

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing